Latest One E-Commerce Corp (ISLT) Headlines
Islet Sciences Inc names Dr Eric Barnett to board
M2 - Tue Jan 07, 5:47AM CST
Biopharmaceutical company Islet Sciences Inc (OTCBB:ISLT) (OTCQB:ISLT) reported on Monday the election of Dr Eric Barnett to its board of directors.
Dr. Eric Barnett Joins Islet Sciences, Inc. Board of Directors
Marketwire - Mon Jan 06, 11:11AM CST
Islet Sciences, Inc. (OTCBB: ISLT) (OTCQB: ISLT) today announced that Dr. Eric Barnett, Executive Vice President at Piedmont Pharmaceuticals LLC, was elected to the Islet Sciences Board of Directors.
Letter to Islet Sciences, Inc. (ISLT) Shareholders From CEO James Green
Marketwire - Thu Dec 12, 7:01AM CST
Islet Sciences, Inc. (OTCBB: ISLT) (OTCQB: ISLT)
Islet Sciences (ISLT) Names James Green and William Wilkison as Chief Executive Officer and Chief Operating Officer
Marketwire - Mon Nov 04, 7:01AM CST
Islet Sciences, Inc., (OTCQB: ISLT) ("Islet" or the "Company") a biopharmaceutical company developing novel technologies for the diagnosis and treatment of diabetes, announced today the appointment of James Green as Chief Executive Officer and William Wilkison, Ph.D. as Chief Operating Officer.
Islet Holdings Files Amended Complaint Against Islet Sciences
GlobeNewswire - Fri Aug 02, 2:56PM CDT
According to Islet Holdings, new allegations of conspiracy and racketeering and a written confession from a scheme participant have led to the resignation of CEO John Steel and the restructuring of the management team at Islet Sciences, Inc. (OTCBB:ISLT). The restructuring was announced after an amended complaint was filed in federal court charging that Islet Sciences has been enticing investments using false documents, and that Steel has "made numerous threats against anyone related to Isletech."
Islet Sciences Begins Restructuring of Company's Senior Management and Board of Directors
Business Wire - Tue Jul 16, 3:51PM CDT
Islet Sciences, Inc., (OTCBB:ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people with diabetes, today announced changes to the company's senior management team and the board of directors.
Islet Sciences Chief Scientific Officer to Present Scientific Studies at Upcoming 12th Congress of the Cell Transplant Society (CTS) in Milan, Italy
Business Wire - Mon Jul 08, 8:44AM CDT
Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people with diabetes, announced today that Dr. Jonathan Lakey, Associate Professor of Surgery and Biomedical Engineering at the University of California Irvine and Chief Scientific Officer and Chairman of the Scientific Advisory Board of Islet Sciences, will be presenting several scientific presentations at the upcoming 12th Congress of the Cell Transplant Society (CTS) in Milan, Italy July 7-11, 2013.
Islet Sciences Chief Scientific Officer Receives $1.27 million in Grant from JDRF to Create Innovative Diabetes Treatments
Business Wire - Thu Jun 27, 3:02PM CDT
Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people with diabetes, announced today that Dr. Jonathan Lakey, Associate Professor of Surgery and Biomedical Engineering at the University of California Irvine and Chief Scientific Officer and Chairman of the Scientific Advisory Board of Islet Sciences, has received $1.27 million in grant funding from the JDRF to develop innovative methods to treat and possibly cure type 1 diabetes. Dr. Jerry Nadler, Dr. Elliot Botvinick and Dr. Paul Johnson, co-investigators in the JDRF grant, are also members of the Company's Scientific Advisory Board.
Islet Sciences, Inc. Technologies Featured in Five Separate Presentations at the American Diabetes Association Annual Meeting
PR Newswire - Mon Jun 24, 6:55AM CDT
Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people with diabetes, announces that its technologies were featured at the American Diabetes Association annual meeting.
Islet Sciences Highlights Abstract at Arteriosclerosis, Thrombosis & Vascular Biology ATVB 2013
Business Wire - Tue May 07, 7:00AM CDT
Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people with diabetes, announced today the acceptance and presentation of an abstract at the recent Arteriosclerosis, Thrombosis & Vascular Biology (ATVB) 2013. The abstract is titled: Signal Transducer and Activation of Transcription (STAT) 4 deficiency reduces adipose tissue inflammation and atherosclerosis.
Islet Sciences Receives Japanese Patent Covering New Medications for Diabetes
Business Wire - Mon Apr 29, 7:41AM CDT
Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people with diabetes, announced today the receipt of a Japanese Patent for allowed claims, Patent Application No. 2008-529208.
Islet Sciences Issues Shareholder Update Letter
Business Wire - Tue Apr 16, 8:02AM CDT
Islet Sciences, Inc., (ISLT) a clinical stage company engaged in the research, development and commercialization of therapeutics in the field of diabetes, issued the following shareholder update letter. Islet Sciences continues to put in place a multi-faceted strategy with one goal: to help combat the global diabetes epidemic. Our mission is to become the leading innovator, developer and provider of therapeutics and diagnostics for diabetes.
Islet Sciences Announces Cell Transplant Journal's Release on Novel Methods of Isolating Piglet Islets
Business Wire - Fri Apr 12, 9:34AM CDT
Islet Sciences, Inc., (ISLT) a clinical stage company engaged in the research, development and commercialization of therapeutics in the field of diabetes, announced today that Cell Transplant Journal released on novel methods of isolating piglet islets, a technology owned by Islet Sciences.
Islet Sciences Receives Notice of Claims Allowance for U.S. Patent Application for New Medications for Treating Diabetes and other Serious Inflammatory Disorders
Business Wire - Wed Apr 03, 8:11AM CDT
Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people with diabetes, announced today the receipt of a Notice of Claims Allowance for its U.S. Patent Application No. 12/036,646. The title of the invention is Lisofylline Analogs and Methods for Use.
Islet Sciences Inc names Dr Eitan Akirav to SAB
M2 - Thu Mar 28, 8:23AM CDT
Biotechnology company Islet Sciences Inc (OTC BB:ISLT) revealed on Wednesday the appointment of Dr Eitan Akirav to its Scientific Advisory Board (SAB).
Islet Sciences Appoints Dr. Eitan Akirav to Scientific Advisory Board
Business Wire - Wed Mar 27, 8:21AM CDT
Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in development and commercialization of patented technologies for the next generation of therapy for persons with Diabetes, today announced that Dr. Eitan Akirav has joined its Scientific Advisory Board.
Islet Sciences Announces Important Study Published in Diabetes Titled "Immune Therapy Reducing B-Cell Death in Type 1 Diabetes"
Business Wire - Wed Mar 13, 7:52AM CDT
Islet Sciences, Inc. (OTCBB:ISLT), (ISLT) a clinical stage company engaged in the research, development and commercialization of therapeutics in the field of diabetes, announced today an important study published in Diabetes by the American Diabetes Association titled Immune Therapy and B-Cell Death in Type 1 Diabetes.
Islet Sciences Announces Inclusion in BioWorld Today Article
PR Newswire - Tue Jan 08, 9:52AM CST
Islet Sciences, Inc., (OTC Bulletin Board: ISLT) a clinical stage company engaged in the research, development and commercialization of therapeutics in the field of diabetes, announced today that it was included in the December 27, 2012 issue of BioWorld Today. A link to the full text of the article is below.
Islet Sciences Inc names Dr Eric Barnett to board
M2 - Tue Jan 07, 5:47AM CST
Biopharmaceutical company Islet Sciences Inc (OTCBB:ISLT) (OTCQB:ISLT) reported on Monday the election of Dr Eric Barnett to its board of directors.
Dr. Eric Barnett Joins Islet Sciences, Inc. Board of Directors
Marketwire - Mon Jan 06, 11:11AM CST
Islet Sciences, Inc. (OTCBB: ISLT) (OTCQB: ISLT) today announced that Dr. Eric Barnett, Executive Vice President at Piedmont Pharmaceuticals LLC, was elected to the Islet Sciences Board of Directors.
Letter to Islet Sciences, Inc. (ISLT) Shareholders From CEO James Green
Marketwire - Thu Dec 12, 7:01AM CST
Islet Sciences, Inc. (OTCBB: ISLT) (OTCQB: ISLT)
Islet Sciences (ISLT) Names James Green and William Wilkison as Chief Executive Officer and Chief Operating Officer
Marketwire - Mon Nov 04, 7:01AM CST
Islet Sciences, Inc., (OTCQB: ISLT) ("Islet" or the "Company") a biopharmaceutical company developing novel technologies for the diagnosis and treatment of diabetes, announced today the appointment of James Green as Chief Executive Officer and William Wilkison, Ph.D. as Chief Operating Officer.
Islet Holdings Files Amended Complaint Against Islet Sciences
GlobeNewswire - Fri Aug 02, 2:56PM CDT
According to Islet Holdings, new allegations of conspiracy and racketeering and a written confession from a scheme participant have led to the resignation of CEO John Steel and the restructuring of the management team at Islet Sciences, Inc. (OTCBB:ISLT). The restructuring was announced after an amended complaint was filed in federal court charging that Islet Sciences has been enticing investments using false documents, and that Steel has "made numerous threats against anyone related to Isletech."
Islet Sciences Begins Restructuring of Company's Senior Management and Board of Directors
Business Wire - Tue Jul 16, 3:51PM CDT
Islet Sciences, Inc., (OTCBB:ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people with diabetes, today announced changes to the company's senior management team and the board of directors.
Islet Sciences Chief Scientific Officer to Present Scientific Studies at Upcoming 12th Congress of the Cell Transplant Society (CTS) in Milan, Italy
Business Wire - Mon Jul 08, 8:44AM CDT
Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people with diabetes, announced today that Dr. Jonathan Lakey, Associate Professor of Surgery and Biomedical Engineering at the University of California Irvine and Chief Scientific Officer and Chairman of the Scientific Advisory Board of Islet Sciences, will be presenting several scientific presentations at the upcoming 12th Congress of the Cell Transplant Society (CTS) in Milan, Italy July 7-11, 2013.
Islet Sciences Chief Scientific Officer Receives $1.27 million in Grant from JDRF to Create Innovative Diabetes Treatments
Business Wire - Thu Jun 27, 3:02PM CDT
Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people with diabetes, announced today that Dr. Jonathan Lakey, Associate Professor of Surgery and Biomedical Engineering at the University of California Irvine and Chief Scientific Officer and Chairman of the Scientific Advisory Board of Islet Sciences, has received $1.27 million in grant funding from the JDRF to develop innovative methods to treat and possibly cure type 1 diabetes. Dr. Jerry Nadler, Dr. Elliot Botvinick and Dr. Paul Johnson, co-investigators in the JDRF grant, are also members of the Company's Scientific Advisory Board.
Islet Sciences, Inc. Technologies Featured in Five Separate Presentations at the American Diabetes Association Annual Meeting
PR Newswire - Mon Jun 24, 6:55AM CDT
Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people with diabetes, announces that its technologies were featured at the American Diabetes Association annual meeting.
Islet Sciences Highlights Abstract at Arteriosclerosis, Thrombosis & Vascular Biology ATVB 2013
Business Wire - Tue May 07, 7:00AM CDT
Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people with diabetes, announced today the acceptance and presentation of an abstract at the recent Arteriosclerosis, Thrombosis & Vascular Biology (ATVB) 2013. The abstract is titled: Signal Transducer and Activation of Transcription (STAT) 4 deficiency reduces adipose tissue inflammation and atherosclerosis.
Islet Sciences Receives Japanese Patent Covering New Medications for Diabetes
Business Wire - Mon Apr 29, 7:41AM CDT
Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people with diabetes, announced today the receipt of a Japanese Patent for allowed claims, Patent Application No. 2008-529208.
Islet Sciences Issues Shareholder Update Letter
Business Wire - Tue Apr 16, 8:02AM CDT
Islet Sciences, Inc., (ISLT) a clinical stage company engaged in the research, development and commercialization of therapeutics in the field of diabetes, issued the following shareholder update letter. Islet Sciences continues to put in place a multi-faceted strategy with one goal: to help combat the global diabetes epidemic. Our mission is to become the leading innovator, developer and provider of therapeutics and diagnostics for diabetes.
Islet Sciences Announces Cell Transplant Journal's Release on Novel Methods of Isolating Piglet Islets
Business Wire - Fri Apr 12, 9:34AM CDT
Islet Sciences, Inc., (ISLT) a clinical stage company engaged in the research, development and commercialization of therapeutics in the field of diabetes, announced today that Cell Transplant Journal released on novel methods of isolating piglet islets, a technology owned by Islet Sciences.
Islet Sciences Receives Notice of Claims Allowance for U.S. Patent Application for New Medications for Treating Diabetes and other Serious Inflammatory Disorders
Business Wire - Wed Apr 03, 8:11AM CDT
Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people with diabetes, announced today the receipt of a Notice of Claims Allowance for its U.S. Patent Application No. 12/036,646. The title of the invention is Lisofylline Analogs and Methods for Use.
Islet Sciences Inc names Dr Eitan Akirav to SAB
M2 - Thu Mar 28, 8:23AM CDT
Biotechnology company Islet Sciences Inc (OTC BB:ISLT) revealed on Wednesday the appointment of Dr Eitan Akirav to its Scientific Advisory Board (SAB).
Islet Sciences Appoints Dr. Eitan Akirav to Scientific Advisory Board
Business Wire - Wed Mar 27, 8:21AM CDT
Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in development and commercialization of patented technologies for the next generation of therapy for persons with Diabetes, today announced that Dr. Eitan Akirav has joined its Scientific Advisory Board.
Islet Sciences Announces Important Study Published in Diabetes Titled "Immune Therapy Reducing B-Cell Death in Type 1 Diabetes"
Business Wire - Wed Mar 13, 7:52AM CDT
Islet Sciences, Inc. (OTCBB:ISLT), (ISLT) a clinical stage company engaged in the research, development and commercialization of therapeutics in the field of diabetes, announced today an important study published in Diabetes by the American Diabetes Association titled Immune Therapy and B-Cell Death in Type 1 Diabetes.
Islet Sciences Announces Inclusion in BioWorld Today Article
PR Newswire - Tue Jan 08, 9:52AM CST
Islet Sciences, Inc., (OTC Bulletin Board: ISLT) a clinical stage company engaged in the research, development and commercialization of therapeutics in the field of diabetes, announced today that it was included in the December 27, 2012 issue of BioWorld Today. A link to the full text of the article is below.
